as on October 21, 2025 at 1:29 am IST
Day's Low
Day's High
2.26%
Downside
4.72%
Upside
52 Week's Low
52 Week's High
19.34%
Downside
43.66%
Upside
Check Exelixis, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$10.6B
EPS (TTM)
2.6647
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
-0.16%
PE Ratio (TTM)
18.87
Industry PE ratio
8.355964912280701
PEG Ratio
2.2685
EBITDA
781.5M
Revenue (TTM)
2.2B
Profit Margin
27.01%
Return On Equity TTM
29.00%
Track how Exelixis, Inc. P/E has moved over time to understand its valuation trends.
Exelixis, Inc. in the last 5 years
Lowest (15.15x)
September 30, 2024
Industry (8.36x)
October 21, 2025
Today (18.87x)
October 21, 2025
Highest (122.74x)
April 30, 2021
Today’s Price to Earnings Ratio: 18.87x
Compare market cap, revenue, PE, and other key metrics of Exelixis, Inc. with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
---|---|---|---|---|---|
BUY | $10.6B | 58.51% | 18.87 | 27.01% | |
BUY | $63.1B | 259.92% | -505.15 | -12.96% | |
NA | $35.3B | NA | NA | -3.89% | |
BUY | $106.9B | 98.27% | 29.67 | 31.86% | |
BUY | $61.3B | 0.76% | 14.58 | 31.37% |
The Exelixis, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Exelixis, Inc. investment value today
Current value as on today
₹1,25,247
Returns
₹25,247
(+25.25%)
Returns from Exelixis, Inc. Stock
₹20,516 (+20.52%)
Dollar Returns*
₹4,730 (+4.73%)
Based on 26 analysts
76.92%
Buy
19.23%
Hold
3.85%
Sell
Based on 26 analysts, 76.92% of analysts recommend a 'BUY' rating for Exelixis, Inc.. Average target price of $44.26
Get share price movements and forecasts by analysts on Exelixis, Inc..
What analysts predicted
21.96%UPSIDE
Target Price
$44.26
Current Price
$34.54
Analyzed by
26 Analysts
Target
$44.26
Exelixis, Inc. target price $44.26, a slight upside of 21.96% compared to current price of $34.54. According to 26 analysts rating.
Search interest for Exelixis, Inc. Stock has increased by 10% in the last 30 days, reflecting an upward trend in search activity.
Time period: to
Change:10% versus previous 30 day period
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Today's Timeline - 20 October
Mon, 12:00 PM
-Exelixis announces detailed results from STELLAR-303 trial, showing zanzalintinib improves overall survival to 10.9 months versus regorafenib.
Mon, 08:18 PM
-Exelixis stock drops 12.17% after sharing detailed results from STELLAR-303 trial, despite positive overall survival findings.
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Revenue Rich
Revenue is up for the last 2 quarters, 555.44M → 568.26M (in $), with an average increase of 2.3% per quarter
Price Rise
In the last 1 year, EXEL stock has moved up by 37.0%
Profit Spike
Netprofit is up for the last 4 quarters, 117.97M → 184.84M (in $), with an average increase of 13.9% per quarter
Against Peers
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 64.9% return, outperforming this stock by 27.9%
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 142.2% return, outperforming this stock by 3.6%
Organisation | Exelixis, Inc. |
Headquarters | 1851 Harbor Bay Parkway, Alameda, CA, United States, 94502 |
Industry | Health Technology |
CEO | Dr. Michael M. Morrissey Ph.D. |
E-voting on shares | Click here to vote |
Name | Title |
---|---|
Ms. Susan T. Hubbard | Executive Vice President of Public Affairs & Investor Relations |
Dr. Anne Champsaur M.D. | Senior Vice President of Drug Safety |
Dr. Stefan Krauss Ph.D. | VP & Head of Business Development |
Dr. Stelios Papadopoulos Ph.D. | Co-Founder & Independent Chair of the Board |
Dr. Dana T. Aftab Ph.D. | Executive Vice President of Research & Development |
Mr. Jeffrey J. Hessekiel J.D. | Executive VP & General Counsel |
Dr. William Berg M.D. | Senior Vice President of Medical Affairs |
Mr. Patrick Joseph Haley M.B.A. | Executive Vice President of Commercial |
Dr. Michael M. Morrissey Ph.D. | CEO, President & Director |
Mr. Christopher J. Senner | Executive VP & CFO |
Exelixis, Inc. share price today is $34.54 as on at the close of the market. Exelixis, Inc. share today touched a day high of $36.17 and a low of $33.76.
Exelixis, Inc. share touched a 52 week high of $49.62 on and a 52 week low of $27.86 on . Exelixis, Inc. stock price today i.e. is closed at $34.54,which is 30.39% down from its 52 week high and 23.98% up from its 52 week low.
Exelixis, Inc. market capitalisation is $0.01T as on .
Indian investors can start investing in Exelixis, Inc. (EXEL) shares with as little as ₹87.9 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹879.00 in Exelixis, Inc. stock (as per the Rupee-Dollar exchange rate as on ).
Based on Exelixis, Inc. share’s latest price of $34.54 as on October 21, 2025 at 1:29 am IST, you will get 0.2895 shares of Exelixis, Inc.. Learn more about
fractional shares .
Exelixis, Inc. stock has given 58.51% share price returns and 21.02% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?